Exhibit 10.21
September 6, 2012
Kamada Ltd.
Science Park
Kiryat Weizmann
7 Sapir St. P.O Box 4081
Ness Ziona 74140, Israel
Attention: Chief Executive Officer
Re: First Amendment (the “First Amendment”) to that EXCLUSIVE MANUFACTURING, SUPPLY AND DISTRIBUTION AGREEMENT (the “Agreement”) dated August 23, 2010 between Kamada Ltd. (“Kamada”) and Baxter Healthcare Corporation (“Baxter”)
Subject to the full execution of this First Amendment, effective as of the date of the last signature, Baxter and Kamada hereby agree to the following:
The parties agree that Section 11.4(d) of this Agreement is modified to read as follows,
“Notification of Complaints. Upon any Party receiving or becoming aware of any complaint involving the A1PI IV Product, it shall act in accordance with the terms of Section 13 (Table No. 7) of the Quality Agreement signed between the Parties on September 23, 2010, as may be amended by the Parties from time to time”.
Except as specifically amended by this Amendment, all other terms and conditions of the Agreement shall continue in full force and effect during the Term of the Agreement.
If the foregoing terms and conditions are acceptable, please sign and date both originals of this First Amendment and return one (1) original to Baxter.
Sincerely, | ACCEPTED: | ||||
Baxter Healthcare Corporation | Kamada Ltd. | ||||
By: | /s/ Ludwig Hantson | By: | /s/ GIL EFRON | /s/ David Tsur | |
Name: | Ludwig Hantson | Name: | GIL EFRON | David Tsur | |
Title: | CVP, President BioScience | Title: | CFO | CEO | |
Date: | Sept 4, 2012 | Date: | Oct 15, 2012 | 15.10.12 |